The Europe Agentic AI In Pharmaceuticals Market is expected to reach USD 316.29 million by 2031, growing at a CAGR of 36.8% during 2026-2033.
The Germany market dominated the Europe Agentic AI In Pharmaceuticals Market by country in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 58.86 million by 2031, growing at a CAGR of 35% during the forecast period.
The Europe Agentic AI in Pharmaceuticals Market has evolved significantly with the growing adoption of autonomous artificial intelligence technologies across pharmaceutical research, drug development, regulatory compliance, and manufacturing operations. Initially, AI applications in the region focused on predictive analytics and data processing; however, advancements in machine learning, natural language processing, and autonomous reasoning capabilities have enabled the emergence of agentic AI systems capable of independently executing complex pharmaceutical workflows. The market is benefiting from strong pharmaceutical innovation ecosystems, increasing investments in digital transformation, and supportive regulatory frameworks encouraging responsible AI adoption across Europe.
Several trends are shaping the market. The increasing focus on explainable and trustworthy AI under the EU AI Act is driving pharmaceutical companies to adopt compliant agentic AI platforms. In addition, growing demand for accelerated drug discovery, optimized clinical trials, intelligent regulatory management, and advanced pharmaceutical data analytics is supporting wider adoption. The emergence of sovereign cloud infrastructure and secure AI ecosystems is further enabling pharmaceutical organizations to deploy agentic AI technologies while maintaining compliance with European data governance requirements.
End User Outlook
Based on End User, the market is segmented into Large Pharmaceutical Companies, Small and Mid-Size Biotech Firms, Contract Research Organizations, and Academic and Research Institutes.
The Large Pharmaceutical Companies market dominated the Europe Agentic AI In Pharmaceuticals Market by End User in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 165.07 million by 2031, growing at a CAGR of 36.2% during the forecast period. The Small and Mid-Size Biotech Firms market is expected to witness a CAGR of 36.1% during 2026-2033.
The Large Pharmaceutical Companies segment accounted for the largest revenue share in 2025 owing to increasing investments in AI-driven drug discovery, clinical development optimization, and pharmaceutical automation initiatives. The Small and Mid-Size Biotech Firms segment witnessed substantial growth supported by increasing adoption of cloud-based AI research platforms and growing biotechnology innovation activities. The Contract Research Organizations segment benefited from rising demand for outsourced clinical research services and AI-powered trial management solutions. The Academic and Research Institutes segment continued expanding through increasing utilization of advanced AI systems for biomedical research and pharmaceutical innovation.
Deployment Mode Outlook
Based on Deployment Mode, the market is segmented into Cloud-Based, Hybrid, and On-Premise.
The Cloud-Based segment dominated the market in 2025 owing to growing demand for scalable computing infrastructure, collaborative research environments, and cost-effective AI deployment models. The Hybrid segment recorded significant growth due to increasing demand for flexible deployment models balancing cloud scalability with enhanced data security and compliance requirements. The On-Premise segment maintained a notable market share among pharmaceutical organizations prioritizing direct control over sensitive research information, intellectual property, and regulatory compliance processes.
Application Outlook
Based on Application, the market is segmented into Clinical-Trial Design and Recruitment, Drug Discovery and Lead Identification, Lead Optimization, Pharmacovigilance and Safety Monitoring, Pre-clinical Development, Manufacturing-Process Optimization, and Other Applications.
The Clinical-Trial Design and Recruitment segment garnered the highest revenue share in 2025 owing to increasing use of AI-powered patient recruitment, protocol optimization, and decentralized clinical trial management solutions. The Drug Discovery and Lead Identification segment recorded strong growth driven by rising deployment of AI-powered molecular analysis and predictive research platforms.
The Lead Optimization segment benefited from increasing adoption of AI-driven simulation and candidate refinement technologies. The Pharmacovigilance and Safety Monitoring segment expanded due to growing demand for automated adverse event monitoring and regulatory reporting systems.
Country Outlook
Based on Country, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Germany and UK led the Europe Agentic AI In Pharmaceuticals Market by Country with a market share of 20.1% and 17.7% in 2025.The France market is expected to witness a CAGR of 37.7% during throughout the forecast period.
Germany dominated the Europe Agentic AI in Pharmaceuticals Market in 2025 owing to its strong pharmaceutical manufacturing base, advanced healthcare infrastructure, and increasing deployment of AI-enabled pharmaceutical innovation platforms. The UK is witnessing significant growth supported by expanding AI research ecosystems, strong biotechnology activity, and increasing adoption of agentic AI across clinical development processes. France continues to strengthen its market position through growing investments in pharmaceutical digitalization and AI-powered healthcare innovation.
List of Key Companies Profiled
By End User
The Germany market dominated the Europe Agentic AI In Pharmaceuticals Market by country in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 58.86 million by 2031, growing at a CAGR of 35% during the forecast period.
The Europe Agentic AI in Pharmaceuticals Market has evolved significantly with the growing adoption of autonomous artificial intelligence technologies across pharmaceutical research, drug development, regulatory compliance, and manufacturing operations. Initially, AI applications in the region focused on predictive analytics and data processing; however, advancements in machine learning, natural language processing, and autonomous reasoning capabilities have enabled the emergence of agentic AI systems capable of independently executing complex pharmaceutical workflows. The market is benefiting from strong pharmaceutical innovation ecosystems, increasing investments in digital transformation, and supportive regulatory frameworks encouraging responsible AI adoption across Europe.
Several trends are shaping the market. The increasing focus on explainable and trustworthy AI under the EU AI Act is driving pharmaceutical companies to adopt compliant agentic AI platforms. In addition, growing demand for accelerated drug discovery, optimized clinical trials, intelligent regulatory management, and advanced pharmaceutical data analytics is supporting wider adoption. The emergence of sovereign cloud infrastructure and secure AI ecosystems is further enabling pharmaceutical organizations to deploy agentic AI technologies while maintaining compliance with European data governance requirements.
End User Outlook
Based on End User, the market is segmented into Large Pharmaceutical Companies, Small and Mid-Size Biotech Firms, Contract Research Organizations, and Academic and Research Institutes.
The Large Pharmaceutical Companies market dominated the Europe Agentic AI In Pharmaceuticals Market by End User in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 165.07 million by 2031, growing at a CAGR of 36.2% during the forecast period. The Small and Mid-Size Biotech Firms market is expected to witness a CAGR of 36.1% during 2026-2033.
The Large Pharmaceutical Companies segment accounted for the largest revenue share in 2025 owing to increasing investments in AI-driven drug discovery, clinical development optimization, and pharmaceutical automation initiatives. The Small and Mid-Size Biotech Firms segment witnessed substantial growth supported by increasing adoption of cloud-based AI research platforms and growing biotechnology innovation activities. The Contract Research Organizations segment benefited from rising demand for outsourced clinical research services and AI-powered trial management solutions. The Academic and Research Institutes segment continued expanding through increasing utilization of advanced AI systems for biomedical research and pharmaceutical innovation.
Deployment Mode Outlook
Based on Deployment Mode, the market is segmented into Cloud-Based, Hybrid, and On-Premise.
The Cloud-Based segment dominated the market in 2025 owing to growing demand for scalable computing infrastructure, collaborative research environments, and cost-effective AI deployment models. The Hybrid segment recorded significant growth due to increasing demand for flexible deployment models balancing cloud scalability with enhanced data security and compliance requirements. The On-Premise segment maintained a notable market share among pharmaceutical organizations prioritizing direct control over sensitive research information, intellectual property, and regulatory compliance processes.
Application Outlook
Based on Application, the market is segmented into Clinical-Trial Design and Recruitment, Drug Discovery and Lead Identification, Lead Optimization, Pharmacovigilance and Safety Monitoring, Pre-clinical Development, Manufacturing-Process Optimization, and Other Applications.
The Clinical-Trial Design and Recruitment segment garnered the highest revenue share in 2025 owing to increasing use of AI-powered patient recruitment, protocol optimization, and decentralized clinical trial management solutions. The Drug Discovery and Lead Identification segment recorded strong growth driven by rising deployment of AI-powered molecular analysis and predictive research platforms.
The Lead Optimization segment benefited from increasing adoption of AI-driven simulation and candidate refinement technologies. The Pharmacovigilance and Safety Monitoring segment expanded due to growing demand for automated adverse event monitoring and regulatory reporting systems.
Country Outlook
Based on Country, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Germany and UK led the Europe Agentic AI In Pharmaceuticals Market by Country with a market share of 20.1% and 17.7% in 2025.The France market is expected to witness a CAGR of 37.7% during throughout the forecast period.
Germany dominated the Europe Agentic AI in Pharmaceuticals Market in 2025 owing to its strong pharmaceutical manufacturing base, advanced healthcare infrastructure, and increasing deployment of AI-enabled pharmaceutical innovation platforms. The UK is witnessing significant growth supported by expanding AI research ecosystems, strong biotechnology activity, and increasing adoption of agentic AI across clinical development processes. France continues to strengthen its market position through growing investments in pharmaceutical digitalization and AI-powered healthcare innovation.
List of Key Companies Profiled
- InSilico Medicine
- Numerion Labs, Inc.
- BenevolentAI Group
- Shenzhen Jingtai Technology Co., Ltd. (XtalPi)
- Recursion Pharmaceuticals, Inc.
- Deep Genomics Incorporated
- Schrödinger, LLC
- Owkin Inc.
- PeptiDream Inc.
- Healx Limited
By End User
- Large Pharmaceutical Companies
- Small and Mid-Size Biotech Firms
- Contract Research Organizations
- Academic and Research Institutes
- Cloud-Based
- Hybrid
- On-Premise
- Clinical-Trial Design and Recruitment
- Drug Discovery and Lead Identification
- Lead Optimization
- Pharmacovigilance and Safety Monitoring
- Pre-clinical Development
- Manufacturing-Process Optimization
- Other Application
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Europe Market1.1 Market Overview
1.2 Key Factors Impacting Market
1.2.1 Market Drivers
1.2.2 Market Restraints
1.2.3 Market Opportunities
1.2.4 Market Challenges
1.2.5 Market Trends
1.2.6 State of Competition
1.2.7 Market Consolidation
1.2.8 Key Customer Criteria
1.3 Product Life Cycle
1.4 Segmentation By End User
1.4.1 Large Pharmaceutical Companies
1.4.2 Small and Mid-Size Biotech Firms
1.4.3 Contract Research Organizations
1.4.4 Academic and Research Institutes
1.5 Segmentation By Deployment Mode
1.5.1 Cloud-Based
1.5.2 Hybrid
1.5.3 On-Premise
1.6 Segmentation By Application
1.6.1 Clinical-Trial Design and Recruitment
1.6.2 Drug Discovery and Lead Identification
1.6.3 Lead Optimization
1.6.4 Pharmacovigilance and Safety Monitoring
1.6.5 Pre-clinical Development
1.6.6 Manufacturing-Process Optimization
1.6.7 Other Application
1.7 Segmentation By Country
1.7.1 Germany
1.7.1.1 Segmentation By End User
1.7.1.1.1 Large Pharmaceutical Companies
1.7.1.1.2 Small and Mid-Size Biotech Firms
1.7.1.1.3 Contract Research Organizations
1.7.1.1.4 Academic and Research Institutes
1.7.1.2 Segmentation By Deployment Mode
1.7.1.2.1 Cloud-Based
1.7.1.2.2 Hybrid
1.7.1.2.3 On-Premise
1.7.1.3 Segmentation By Application
1.7.1.3.1 Clinical-Trial Design and Recruitment
1.7.1.3.2 Drug Discovery and Lead Identification
1.7.1.3.3 Lead Optimization
1.7.1.3.4 Pharmacovigilance and Safety Monitoring
1.7.1.3.5 Pre-clinical Development
1.7.1.3.6 Manufacturing-Process Optimization
1.7.1.3.7 Other Application
1.7.2 UK
1.7.2.1 Segmentation By End User
1.7.2.1.1 Large Pharmaceutical Companies
1.7.2.1.2 Small and Mid-Size Biotech Firms
1.7.2.1.3 Contract Research Organizations
1.7.2.1.4 Academic and Research Institutes
1.7.2.2 Segmentation By Deployment Mode
1.7.2.2.1 Cloud-Based
1.7.2.2.2 Hybrid
1.7.2.2.3 On-Premise
1.7.2.3 Segmentation By Application
1.7.2.3.1 Clinical-Trial Design and Recruitment
1.7.2.3.2 Drug Discovery and Lead Identification
1.7.2.3.3 Lead Optimization
1.7.2.3.4 Pharmacovigilance and Safety Monitoring
1.7.2.3.5 Pre-clinical Development
1.7.2.3.6 Manufacturing-Process Optimization
1.7.2.3.7 Other Application
1.7.3 France
1.7.3.1 Segmentation By End User
1.7.3.1.1 Large Pharmaceutical Companies
1.7.3.1.2 Small and Mid-Size Biotech Firms
1.7.3.1.3 Contract Research Organizations
1.7.3.1.4 Academic and Research Institutes
1.7.3.2 Segmentation By Deployment Mode
1.7.3.2.1 Cloud-Based
1.7.3.2.2 Hybrid
1.7.3.2.3 On-Premise
1.7.3.3 Segmentation By Application
1.7.3.3.1 Clinical-Trial Design and Recruitment
1.7.3.3.2 Drug Discovery and Lead Identification
1.7.3.3.3 Lead Optimization
1.7.3.3.4 Pharmacovigilance and Safety Monitoring
1.7.3.3.5 Pre-clinical Development
1.7.3.3.6 Manufacturing-Process Optimization
1.7.3.3.7 Other Application
1.7.4 Russia
1.7.4.1 Segmentation By End User
1.7.4.1.1 Large Pharmaceutical Companies
1.7.4.1.2 Small and Mid-Size Biotech Firms
1.7.4.1.3 Contract Research Organizations
1.7.4.1.4 Academic and Research Institutes
1.7.4.2 Segmentation By Deployment Mode
1.7.4.2.1 Cloud-Based
1.7.4.2.2 Hybrid
1.7.4.2.3 On-Premise
1.7.4.3 Segmentation By Application
1.7.4.3.1 Clinical-Trial Design and Recruitment
1.7.4.3.2 Drug Discovery and Lead Identification
1.7.4.3.3 Lead Optimization
1.7.4.3.4 Pharmacovigilance and Safety Monitoring
1.7.4.3.5 Pre-clinical Development
1.7.4.3.6 Manufacturing-Process Optimization
1.7.4.3.7 Other Application
1.7.5 Spain
1.7.5.1 Segmentation By End User
1.7.5.1.1 Large Pharmaceutical Companies
1.7.5.1.2 Small and Mid-Size Biotech Firms
1.7.5.1.3 Contract Research Organizations
1.7.5.1.4 Academic and Research Institutes
1.7.5.2 Segmentation By Deployment Mode
1.7.5.2.1 Cloud-Based
1.7.5.2.2 Hybrid
1.7.5.2.3 On-Premise
1.7.5.3 Segmentation By Application
1.7.5.3.1 Clinical-Trial Design and Recruitment
1.7.5.3.2 Drug Discovery and Lead Identification
1.7.5.3.3 Lead Optimization
1.7.5.3.4 Pharmacovigilance and Safety Monitoring
1.7.5.3.5 Pre-clinical Development
1.7.5.3.6 Manufacturing-Process Optimization
1.7.5.3.7 Other Application
1.7.6 Italy
1.7.6.1 Segmentation By End User
1.7.6.1.1 Large Pharmaceutical Companies
1.7.6.1.2 Small and Mid-Size Biotech Firms
1.7.6.1.3 Contract Research Organizations
1.7.6.1.4 Academic and Research Institutes
1.7.6.2 Segmentation By Deployment Mode
1.7.6.2.1 Cloud-Based
1.7.6.2.2 Hybrid
1.7.6.2.3 On-Premise
1.7.6.3 Segmentation By Application
1.7.6.3.1 Clinical-Trial Design and Recruitment
1.7.6.3.2 Drug Discovery and Lead Identification
1.7.6.3.3 Lead Optimization
1.7.6.3.4 Pharmacovigilance and Safety Monitoring
1.7.6.3.5 Pre-clinical Development
1.7.6.3.6 Manufacturing-Process Optimization
1.7.6.3.7 Other Application
1.7.7 Rest of Europe
1.7.7.1 Segmentation By End User
1.7.7.1.1 Large Pharmaceutical Companies
1.7.7.1.2 Small and Mid-Size Biotech Firms
1.7.7.1.3 Contract Research Organizations
1.7.7.1.4 Academic and Research Institutes
1.7.7.2 Segmentation By Deployment Mode
1.7.7.2.1 Cloud-Based
1.7.7.2.2 Hybrid
1.7.7.2.3 On-Premise
1.7.7.3 Segmentation By Application
1.7.7.3.1 Clinical-Trial Design and Recruitment
1.7.7.3.2 Drug Discovery and Lead Identification
1.7.7.3.3 Lead Optimization
1.7.7.3.4 Pharmacovigilance and Safety Monitoring
1.7.7.3.5 Pre-clinical Development
1.7.7.3.6 Manufacturing-Process Optimization
1.7.7.3.7 Other Application
Chapter 2. Company Snapshot
2.1 InSilico Medicine
2.1.1 Business Overview
2.1.2 Key Information
2.1.3 Company Focus
2.1.4 Strategic Insights
2.1.5 Strategy Deployed
2.1.6 Product & Service Portfolio
2.1.7 Capability Overview
2.1.8 Technology & Innovation Focus
2.1.9 Customers / End Users
2.1.10 Competitive Positioning
2.1.11 Key Differentiators
2.1.12 Portfolio Matrix
2.1.13 SWOT Analysis
2.1.14 Future Outlook
2.2 Numerion Labs, Inc.
2.2.1 Business Overview
2.2.2 Key Information
2.2.3 Company Focus
2.2.4 Strategic Insights
2.2.5 Strategy Deployed
2.2.6 Product & Service Portfolio
2.2.7 Capability Overview
2.2.8 Technology & Innovation Focus
2.2.9 Customers / End Users
2.2.10 Competitive Positioning
2.2.11 Key Differentiators
2.2.12 Portfolio Matrix
2.2.13 SWOT Analysis
2.2.14 Future Outlook
2.3 BenevolentAI Group
2.3.1 Business Overview
2.3.2 Key Information
2.3.3 Company Focus
2.3.4 Strategic Insights
2.3.5 Strategy Deployed
2.3.6 Product & Service Portfolio
2.3.7 Capability Overview
2.3.8 Technology & Innovation Focus
2.3.9 Customers / End Users
2.3.10 Competitive Positioning
2.3.11 Key Differentiators
2.3.12 Portfolio Matrix
2.3.13 SWOT Analysis
2.3.14 Future Outlook
2.4 Shenzhen Jingtai Technology Co., Ltd (XtalPi)
2.4.1 Business Overview
2.4.2 Key Information
2.4.3 Company Focus
2.4.4 Strategic Insights
2.4.5 Strategy Deployed
2.4.6 Product & Service Portfolio
2.4.7 Capability Overview
2.4.8 Technology & Innovation Focus
2.4.9 Customers / End Users
2.4.10 Competitive Positioning
2.4.11 Key Differentiators
2.4.12 Portfolio Matrix
2.4.13 SWOT Analysis
2.4.14 Future Outlook
2.5 Recursion Pharmaceuticals, Inc.
2.5.1 Business Overview
2.5.2 Key Information
2.5.3 Company Focus
2.5.4 Strategic Insights
2.5.5 Strategy Deployed
2.5.6 Product & Service Portfolio
2.5.7 Capability Overview
2.5.8 Technology & Innovation Focus
2.5.9 Customers / End Users
2.5.10 Competitive Positioning
2.5.11 Key Differentiators
2.5.12 Portfolio Matrix
2.5.13 SWOT Analysis
2.5.14 Future Outlook
2.6 Deep Genomics Incorporated
2.6.1 Business Overview
2.6.2 Key Information
2.6.3 Company Focus
2.6.4 Strategic Insights
2.6.5 Strategy Deployed
2.6.6 Product & Service Portfolio
2.6.7 Capability Overview
2.6.8 Technology & Innovation Focus
2.6.9 Customers / End Users
2.6.10 Competitive Positioning
2.6.11 Key Differentiators
2.6.12 Portfolio Matrix
2.6.13 SWOT Analysis
2.6.14 Future Outlook
2.7 Schrödinger, LLC
2.7.1 Business Overview
2.7.2 Key Information
2.7.3 Company Focus
2.7.4 Strategic Insights
2.7.5 Strategy Deployed
2.7.6 Product & Service Portfolio
2.7.7 Capability Overview
2.7.8 Technology & Innovation Focus
2.7.9 Customers / End Users
2.7.10 Competitive Positioning
2.7.11 Key Differentiators
2.7.12 Portfolio Matrix
2.7.13 SWOT Analysis
2.7.14 Future Outlook
2.8 Owkin Inc.
2.8.1 Business Overview
2.8.2 Key Information
2.8.3 Company Focus
2.8.4 Strategic Insights
2.8.5 Strategy Deployed
2.8.6 Product & Service Portfolio
2.8.7 Capability Overview
2.8.8 Technology & Innovation Focus
2.8.9 Customers / End Users
2.8.10 Competitive Positioning
2.8.11 Key Differentiators
2.8.12 Portfolio Matrix
2.8.13 SWOT Analysis
2.8.14 Future Outlook
2.9 PeptiDream Inc.
2.9.1 Business Overview
2.9.2 Key Information
2.9.3 Company Focus
2.9.4 Strategic Insights
2.9.5 Strategy Deployed
2.9.6 Product & Service Portfolio
2.9.7 Capability Overview
2.9.8 Technology & Innovation Focus
2.9.9 Customers / End Users
2.9.10 Competitive Positioning
2.9.11 Key Differentiators
2.9.12 Portfolio Matrix
2.9.13 SWOT Analysis
2.9.14 Future Outlook
2.10 Healx Limited
2.10.1 Business Overview
2.10.2 Key Information
2.10.3 Company Focus
2.10.4 Strategic Insights
2.10.5 Strategy Deployed
2.10.6 Product & Service Portfolio
2.10.7 Capability Overview
2.10.8 Technology & Innovation Focus
2.10.9 Customers / End Users
2.10.10 Competitive Positioning
2.10.11 Key Differentiators
2.10.12 Portfolio Matrix
2.10.13 SWOT Analysis
2.10.14 Future Outlook
Companies Mentioned
- InSilico Medicine
- Numerion Labs, Inc.
- BenevolentAI Group
- Shenzhen Jingtai Technology Co., Ltd. (XtalPi)
- Recursion Pharmaceuticals, Inc.
- Deep Genomics Incorporated
- Schrödinger, LLC
- Owkin Inc.
- PeptiDream Inc.
- Healx Limited
